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MORRIS TAGERt
The mechanism of the coagulation of blood by staphylocoagulase and the
relation of this process to physiological clotting present many unsolved
problems. Evidence has been advanced for the concept that coagulase reacts
with a plasma component (coagulase reacting factor CRF) which is dis-
tinct from prothrombin.5'4'1S1 The formation of an intermediate complex
has been inferred from the shortening of the clotting time when some
preparations of coagulase and plasma are incubated before the addition of
fibrinogen.",6 A simplified representation of the reaction may thus be
assumed to proceed along these lines:
Coagulase plus CRF = intermediate complex
Intermediate complex plus fibrinogen = fibrin
The evidence for the differentiation of CRF from prothrombin has been
presented elsewhere."' That this concept has not been accepted without
reservations is evident from the recent studies of Duthie and Lorenz,3" who
are not entirely convinced that prothrombin and CRF are separate entities
and reconsider the possibility that CRF and prothrombin may be identical,
or that CRF may be a modification of prothrombin. With regard to the
formation of the "intermediate complex," while a shortening of the coagula-
tion time when coagulase and plasma are incubated has been frequently
noted, incubation of some preparations of plasma and coagulase, in past
(unpublished) studies, failed to produce any significant acceleration of
clotting.
These problems of coagulase clotting have prompted the present study of
the action of trypsin and its inhibitor on this system. The acceleration of
physiological clotting by trypsin has been recognized for many years,2"' and
more recently, the inhibitory capacities of trypsin inhibitors, such as the
soybean trypsin inhibitor of Kunitz have been established.1 ' 8', The
isolation of these agents in crystalline form'" has helped to resolve earlier
conflicts' which stemmed from the use of impure reagents in improper
amounts. The primary purpose of the present study, therefore, was to
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investigate the action of the trypsin and its inhibitor on coagulase clotting,
with the object of possibly disclosing some differences from, or similarities
to, the mode of action of these agents on physiological clotting. The use of
the enzyme inhibitor was further suggested as a means of investigating the
mechanism of CRF loss when blood coagulates. In a recent study,'9 this
CRF consumption has been shown to depend on prothrombin conversion.
Since this reaction constitutes a possible link between the coagulase and
the physiological clotting systems, and since there is evidence that pro-
teolysis occurs during prothrombin conversion, the effect of the tryptic
inhibitor on this reaction seemed worthy of study.
MATERIALS AND METHODS
Coagulase-a partially purified cell-free product derived from Staphylococcus aureus
$104'1 was used throughout.
Plasma-dilutions of citrated human blood bank discards were used as the source
of CRF.
Fibrinogen-Armour's bovine Fraction I was employed in a concentration of 200
mgs. per cent in veronal buffer at a pH of 7.2.
Trypsin-twice crystallized lot TR 340 (Worthington Biochemicals) was dissolved
in 0.9% saline, and was dialyzed against 1/1000 M HCl; 150 mgs. of the original
material was estimated to contain 60 mgs. of protein.
Trypsin inhibitor five times crystallized-Soybean trypsin inhibitor (SBTI), lots
S 55 and S 62 (Worthington Biochemicals) were dissolved in M/15 phosphate buffer
at a pH of 7.1, and subdilutions were made in physiological saline.
All the above reagents were made up in small lots, and maintained in the deep freeze
unit at about -15° C.
General method of determining the clotting timte. Tests were made in pyrex glass
tubes 7 X 12 mm., using a 2x magnifying lens and a constant fluorescent light source.
The time of the appearance of the first wisp of fibrin or of fine floccules was taken as
the clotting time and was recorded to the nearest second with a stopwatch. Further
details of procedures are considered under RESULTS.
RESULTS
The effect of crystalline trypsin on the coagulase clotting of plasma.
Previous studies have demonstrated that crude and crystalline trypsin will
inactivate coagulase."'2X For the present purposes, therefore, minute
amounts of trypsin were selected which produced no evident fall in coagu-
lase titer during the period of observation. Both the plasma and the trypsin
dilutions were made in citrated saline. Trypsin at the concentrations indi-
cated in Table 1, the plasma dilution, and coagulase were mixed in equal
volumes, and 0.2 ml. samples were withdrawn and reacted with 0.2 ml. of
fibrinogen at the stated times. The potentiating effect of 1 microgram and of
0.5 micrograms of trypsin was readily apparent, while 0.1 micrograms/ml.
of trypsin was without effect. Even this minute amount, however, accelerated
physiological clotting (Table 2).
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In subsequent experiments, heparin in excess was also added to the
plasma before reacting with trypsin and coagulase. The same acceleration
of clotting in the test system was noted, while no clotting was noted in the
trypsin-plasma controls at any of the levels observed.
TABLE 1
POTENTIATION OF COAGULASE CLOTTING BY TRYPSIN
Incubation mixture*
Test Tryp- Plas- Coagu- Clotting time in min. & sec. at
no. sint mat lase 0 10' 20' 30' 40'
1 1 0.5 0.5 7' 30" 4' 1" 2' 30" 2' 20" 2' 40"
2 0.5 0.5 0.5 7' 43 6' 6" 3' 56" 3 43" 4'
3 0.1 0.5 0.5 11' 8'40" 6'51" 6'28" 6' 17"
4 0 0.5 0.5 10'55" 8'45" 6' 47" 6' 33" 6' 33"
5 1 0.5 0 60-120' 60-120' 60-120' 60-120' 60-120'
6 0.5 0.5 0 0 0 0 0 0
7 0.1 0.5 0 0 0 0 0 0
* All volumes made up to 1.5 ml.
t Final concentration in micrograms/ml. in the incubation mixture.
4 Plasma diluted 1: 50 in saline and 0.3%o sodium citrate.
TABLE 2
THE EFFECT OF TRYPSIN ON PHYSIOLOGICAL CLOTTING
Prothrombin
conversion mixture*
Test Tryp- Plas- Clotting time in min. & sec. at
no. sint Ca(0.02M) mat 0 15' 30' 10 10301
1 1 0.5 0.5 16' 30" 4' 2' 52" 2 09" 2' 04"
2 0.1 0.5 0.5 45' 10'42" 8'25" 1' 25" 1'24"
3 1 0 0.5 1° 20' 25' 15' 10'
4 0.1 0 0.5 No clot No clot No clot No clot No clot
at 1%2
5 0 0.5 0.5 1°15' 10+ 45' 2'30" 1'2"
* All volumes made up to 1.5 ml.
t Final concentration in micrograms/ml. in the incubation mixture.
1 Plasma diluted 1: 50 in saline.
The effect of SBTI on the clotting of blood by coagulase. The accelera-
tion of both physiological and coagulase clotting by trypsin prompted a
study of the activity of the tryptic inhibitor (SBTI) on the coagulase-
CRF reaction. The inhihition of physiological clotting by SBTI has been
repeatedly demonstrated although the site of action is not definitively estab-
lished. As little as 2.5 micrograms/ml. have been shown to exert an inhibi-
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tory effect on thrombin formation.8 Preliminary titrations indicated that the
incubation of SBTI and coagulase for 1 hour at 370 C. failed to exert any
effect at levels exceeding 1000 micrograms/ml. Only very high concentra-
TABLE 3
THE EFFECT OF SBTI ON CLOTTING OF BLOOD BY COAGULASE
Incubationt mixture* Clotting time in min. & sec at
Test
no. SBTIt Coagulase Plasmat 0 15' 30' 60'
1 6600 0.5 0.5 7' 40" 5' 15" 3' 55" 4' 5"
2 660 0.5 0.5 6' 57" 4'30" 4' 31" 4 8
3 66 0.5 0.5 6' 40" 4' 25" 4' 25" 4' 16"
4 6.6 0.5 0.5 6' 10" 4' 13" 4' 13" 4' 2"
5 0 0.5 0.5 6' 30" 4' 45" 4'45" 4' 7"
6 6600 0 0.5 0 0 0 0
7 660 0 0.5 0 0 0 0
8 66 0 0.5 0 0 0 0
9 6.6 0 0.5 0 0 0 0
* All volumes made up to 1.5 ml.
t Final concentration in micrograms/ml. in the incubation mixture.
t Plasma diluted 1: 50 in saline and 0.3% sodium citrate and 0.1 mg. heparin/ml.
TABLE 4
THE NEUTRALIZATION BY AN EXCESS OF SBTI OF THE EFFECT OF TRYPSIN
ON THE COAGULASE CLOTTING OF PLASMA
Incubation mixture*
Tryp- Clotting time in min. & sec. at Test Tryp- sin & Coagu- _
no. sint SBTI SBTIt Plasma¶, lase 0 10' 20' 30'
1 1 0 0 0.5 0.5 7' 40" 3' 13" 2' 41" 2' 36"
2 0 250 0 0.5 0.5 7' 25" 4' 50" 4' 44" 4' 50"
3 0 0 0.5 0.5 0.5 7' 05" 5' 5' 10" 4' 25"
4 0 0 0 0.5 0.5 8' 10" 5' 25" 5' 25" 4' 50"
5 1 0 0 0.5 0 0 0 0 0
6 0 250 0 0.5 0 0 0 0 0
7 0 0 0.5. 0.5 0 0 0 0 0
* All volumes made up to 1.5 ml.
t Final concentration in micrograms/ml. in the incubation mixture.
t Mixture of equal parts of SBTI and trypsin to give final concentration of 1 micro-
gram of trypsin/ml. and 250 micrograms of SBTI/ml.
1T Plasma diluted 1: 50 in saline and 0.3% sodium citrate and 0.1 mg. heparin/ml.
tions, such as 6,000-12,000 micrograms/ml. produced some prolongation of
the clotting time. Attention was, therefore, directed towards evaluating the
possibility that SBTI may interfere in the coagulase-CRF reaction. Accord-
ingly, equal volumes of various concentrations of SBTI, of suitable plasma
dilutions, and of coagulase were mixed, and 0.2 ml. of the incubation mix-
ture added to 0.2 ml. of fibrinogen at various time intervals. It will be notedTRYPSIN INHIBITORS AND BLOOD CLOTTING
(Table 3) that the coagulase clotting system proved highly refractory to the
action of SBTI. Only at excessively high levels is there a delay in the initial
clotting time-comparable to the effect on preincubating the inhibitor and
coagulase-while the shortening of the coagulation time upon incubation of
coagulase and CRF is not blocked even at these excessive levels of inhibitor.
In subsequent experiments, modifications of the above procedure were
explored in seeking conditions which might reveal a significant effect.
Dilutions of plasma, from 1: 10 to 1: 1000 were tested against a range of
coagulase dilutions, as well as plasma samples which had been subjected to
five successive Seitz filtrations to remove prothrombin activity. Neither was
any significant effect on the initial clotting time noted except at the very
high levels of inhibitor, nor was the shortening of the clotting time follow-
TABLE 5
THE EFFECT OF SBTI ON CRF LosS AFTER PROTHROMBIN CONVERSION
Prothrombin conversion Residual CRF clot-
incubation mixture* ting time at final
Test Thrombo- serum dilutions of
no. SBTIt Ca(0.02M) plastin Plasma 1,: 30 1: 150
1 4000 0.2 0.2 0.2 2' 05" 5' 30"
2 400 0.2 0.2 0.2 2' 21" 5'47"
3 40 0.2 0.2 0.2 3' 7' 35"
4 4 0.2 0.2 0.2 3' 57" 8' 36"
5 0.4 0.2 0.2 0.2 3' 54" 8' 20"
6 0.04 0.2 0.2 0.2 4' 6" 9' 04"
7 0.004 0.2 0.2 0.2 4' 9" 10' 19"
8 0 0.2 0.2 0.2 4' 54" 12' 36"
9 0 0 0.2 0.2 1' 35" 3' 30"
* All volumes made up to 1 ml. with veronal buffer.
t Final concentration in micrograms/ml. in the incubation mixture.
Thrombin controls on test, by omitting coagulase: no clots in 1 hour.
ing the incubation of coagulase and CRF blocked at any level of inhibitor
tested. In a further titration, a great excess of SBTI was added to trypsin
at a final concentration of 1 microgram/ml. and then reacted with coagulase
and plasma. The superimposed accelerating effect of trypsin was abolished,
but not the base-line speeding up of the reaction such as occurred in the
controls (Table 4).
The effect of SBTI on the CRF loss incurred during prothrombin con-
version. It has been shown that the conversion of plasma to serum results
in a loss of CRF.4"''9 and that conditions which favor the most effective
prothrombin conversion bring about maximal CRF loss. Since SBTI inter-
ference with the physiological coagulation presumably involves prothrom-
bin conversion, it seemed indicated to determine whether interference with
proteolysis would spare CRF. In the experiment summarized in Table 5,
529YALE JOURNAL OF BIOLOGY AND MEDICINE
plasma was converted by calcium and thromboplastin (rabbit brain), and
various concentrations of SBTI were incorporated in the conversion mix-
ture. After coagulation occurred, the clots were shaken loose, and the sam-
ples incubated at 370 C. for two hours to allow antithrombin to form. The
sera were then diluted, and aliquots titrated for CRF by the addition of co-
agulase and fibrinogen. It will be noted that as little as 0.4 micrograms/ml.
of SBTI (#5) partially blocked CRF loss, while the effect of the further
dilutions of the SBTI approached the conversion control (#8). On the
other hand, even at the maximal concentration of SBTI tested, 4000 micro-
grams/ml. (#1), the residual CRF titer did not attain the level of the
sample in which no prothrombin conversion occurred (#9). Subsequent
experiments were confirmatory of these findings. Finally, the removal of
directly demonstrable prothrombin activity by five successive Seitz filtra-
tions abolished CRF loss regardless of the addition of calcium, thrombo-
plastin, or SBTI.
DISCUSSION
Many observations have favored the distinctiveness of coagulase clotting
from the physiological process. Among these may be mentioned the failure
of citrate, oxalate, and of heparin to interfere with coagulase activity.
Highly purified bovine prothrombin of Seegers is all but completely devoid
of CRF even when reacted with coagulase preparations of high potency and
purity."8 The dissociation of prothrombin activity from CRF by serial Seitz
filtration also supports this concept."
That many of the arguments admit of alternative interpretations cannot
be denied. Thus, the activation of prothrombin by systems other than cal-
cium and "thromboplastin" is receiving wide recognition. It is known that
Seitz filtration does not eliminate all prothrombin activity,"" and that,
indeed, some additional activity may be regenerated by appropriate chem-
ical procedures from what appear to be prothrombin-free filtrates. Duthie
and Lorenz' suggest that it may be conceivable that repeated Seitz filtration
may actually not remove prothrombin, but that this procedure so alters it
that, while it can no longer be converted to thrombin, it still retains its
ability to react with coagulase. It is of interest in this regard to note that
CRF properties are modified when separation from prothrombin is achieved
by serial Seitz filtration,= suggesting, though not proving, a possible close
relationship between the two agents in the native state. Duthie and Lorenz'
also interpret parallel CRF and prothrombin loss consequent on prothrom-
bin conversion, as well as the similar effects of dicoumarol administration
on prothrombin and CRF, as pointing in the same direction.
The present writer continues to favor the view that prothrombin and
CRF are not identical, and that the two clotting mechanisms are distinct.
Final solution of the problem awaits adequate purification of CRF.
Attempts in this direction have met with only limited success. Although
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purification of the order of one hundred and twenty-five-fold has been
attained, the products proved highly labile and were not free of slight traces
of prothrombin activity.=
The studies here reported have afforded a further basis for comparison of
the two clotting systems. Both responded to minute concentrations of added
trypsin. The coagulase clotting system, however, proved all but completely
refractory when tested against excessively high levels of two lots of inhibi-
tor. There was no evidence of any effect on the initial clotting time except
at very high levels of SBTI, and the formation of the "interinediate com-
plex" was not blocked at any level of inhibitor tested. The same lots of
SBTI, in minute amounts, proved effective in delaying the clotting of
citrated plasma by recalcification. If the activation of prothrombin involves
proteolytic enzyme systems vulnerable to SBTI, then the coagulase reaction
either involves proteolytic enzyme systems of different specificities or
proceeds along diverse pathways altogether.
The acceleration of the clotting of plasma by the addition. of minute
quantities of trypsin to coagulase suggests the need for caution in the inter-
pretation of the formation of an "intermediate complex" when coagulase
and CRF are incubated. The presence of proteolytic enzymes in either
crude coagulase' or in plasma may contribute to such acceleration. How-
ever, in the present studies, the order of acceleration resulting from the
incubation of partially purified coagulase and diluted plasma was far
slighter than the shortening of the clotting time occurring when trypsin
was added. It is noteworthy, too, that while an excess of SBTI abolishes
the superimposed accelerating effect of trypsin, the base-line acceleration is
not disturbed. The suggestion may be entertained that some of the more
striking accelerations""' reported in the literature when coagulase and CRF
are incubated may represent a summation of a true "intermediate complex"
and the activity of contaminating proteolytic enzymes.
Milstone'5 has presented evidence that the thrombokinase, the activator
of prothrombin, is an enzyme, possibly proteolytic. The sparing effect of
minute quantities of SBTI on CRF loss after prothrombin conversion-
quite within the range of trypsin and trypsin inhibitor activity on physio-
logical clotting-makes it seem acceptable that proteolysis occurring during
prothrombin conversion is the mechanism underlying this CRF loss.
SUMMARY
Crystalline trypsin at concentrations of the order of 0.5 to 1 micro-
gram/ml., accelerates the clotting of plasma by coagulase.
Contrary to its effect on physiological clotting, crystalline soybean tryp-
sin inhibitor (SBTI) fails to influence the coagulase clotting process, with
the exception that a slight prolongation of initial clotting time takes place
at high levels of inhibitor.
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SBTI effectively, though not completely, blocks CRF loss incurred
during prothrombin conversion.
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